Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma


Kolamunnage-Dona, Ruwanthi ORCID: 0000-0003-3886-6208, Berhane, Sarah, Potts, Harry, Williams, Edward H, Tanner, James, Janowitz, Tobias, Hoare, Matthew and Johnson, Philip (2021) Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. JOURNAL OF HEPATOLOGY, 75 (4). 879 - 887.

[img] Text
JHEPAT-D-20-02052 Accepted.docx - Accepted Version
Access to this file is embargoed until 27 May 2022.
Download (3MB)
Item Type: Article
Uncontrolled Keywords: hepatocellular carcinoma, hepatitis C virus, tumour progression rate, sorafenib, joint modelling
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Population Health
Depositing User: Symplectic Admin
Date Deposited: 10 May 2021 10:45
Last Modified: 25 May 2022 07:13
DOI: 10.1016/j.jhep.2021.05.015
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3121523
Dimensions
Altmetric
CORE (COnnecting REpositories)